Day One Biopharmaceuticals, Inc. Common Stock (DAWN) is a publicly traded Healthcare sector company. As of May 21, 2026, DAWN trades at $21.53 with a market cap of $2.22B and a P/E ratio of -20.70. DAWN moved +0.14% today. Year to date, DAWN is +158.15%; over the trailing twelve months it is +193.72%. Its 52-week range spans $5.64 to $21.53. Analyst consensus is buy with an average price target of $23.75. Rallies surfaces DAWN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Day One Biopharma Faces Fiduciary Probe Over $21.50 Per Share Servier Sale: Day One Biopharmaceuticals' sale to Servier for $21.50 per share is under investigation by Halper Sadeh LLC for potential federal securities violations and breaches of fiduciary duties. The firm warns insiders could receive substantial benefits and terms may limit superior competing offers for shareholders.
| Metric | Value |
|---|---|
| Price | $21.53 |
| Market Cap | $2.22B |
| P/E Ratio | -20.70 |
| EPS | $-1.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.53 |
| 52-Week Low | $5.64 |
| Volume | 2.99M |
| Avg Volume | 0 |
| Revenue (TTM) | $158.18M |
| Net Income | $-107.32M |
| Gross Margin | 0.00% |
12 analysts cover DAWN: 0 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.75.